Depression and Clinical Outcomes in Heart Failure: An OPTIMIZE-HF Analysis

 Funding: See last page of article.Conflict of Interest: See last page of article.Authorship: See last page of article.

 Funding: GlaxoSmithKline (GSK) funded both the OPTIMIZE-HF registry and this analysis of registry data. The OPTIMIZE-HF registry was established by GSK under the guidance of a steering committee of academic advisors, each of whom is an author on this manuscript. These academic advisors were intimately involved in the initial preparation, design, and data collection for this registry. GSK provided financial and material support for the OPTIMIZE-HF registry. Outcome, Inc. (Cambridge, Mass) created the web-based data collection tool for OPTIMIZE-HF, performed data checks, and stored site-specific and aggregate data.

 Conflict of Interest: Nancy M. Albert, PhD, RN, reported that she is a consultant for Medtronic and GSK. She is on the speaker's bureau for GSK and Scios, Inc.Gregg C. Fonarow, MD, reported that he has received research grants from GSK, Medtronic, Pfizer, and the NHLBI. He has received honoraria from Medtronic and GSK. He is a consultant for GSK, Medtronic, and Scios.William T. Abraham, MD, reported that he has received a research grant from Amgen, Biotronik, CHF Solutions, GSK, HFA, NIH, Medtronic, Myogen, Orqis Medical, Otsuka Maryland Research Institute, Paracor Inc., and Scios, Inc. He is a consultant/on the speakers bureau for Amgen, AstraZeneca, Boehringer-Ingelheim, CHF Solutions, GSK, Guidant, Medtronic, Merck, Pfizer, ResMed, Respironics, Scios, Inc., and St. Jude Medical. He is on the Advisory Board of CardioKinetix, Inc., CHF Solutions, Department of Veterans Affairs Cooperative Studies Program, NIH, and Savacor, Inc. He has received honoraria from AstraZeneca, Boehringer-Ingelheim, GSK, Guidant, Medtronic, Merck, Pfizer, ResMed, Respironics, Scios, Inc., and St. Jude Medical.Mihai Gheorghiade, MD, reported that he is a consultant and has received honoraria from Otsuka, Protein Design Lab, Sigma Tau, Medtronic, Pfizer, and GSK.Barry H. Greenberg, MD, reported that he is on the speaker's bureau for GSK, AstraZeneca, Pfizer, Merck, and Novartis. He is a consultant for GSK, Osuka and Sanofi Aventis.Eduardo Nunez, MD, reported that he is an employee (cardiovascular epidemiologist) at GSK.Christopher M. O'Connor, MD, reported that he is a consultant for Amgen, GSK, Guidant, Medtronic, Merck, Novartis, Otsuka, Pfizer, and Scios, Inc.Wendy G. Stough, PharmD, reported that she has received a research grant, is a consultant, and is on the speaker's bureau for GSK.Clyde W. Yancy, MD, reported that he has received research grants from GSK, Scios, Inc., Medtronic, and NitroMed. He also is a consultant for Scios, Inc., GSK, Medtronic, NitroMed, and CHF Solutions.James B. Young, MD, reported that he has received research grants from and is a consultant for AstraZeneca and GSK.

 Authorship: With respect to this study using registry data and the resulting manuscript, the OPTIMIZE-HF steering committee had access to all study data and takes full responsibility for the accuracy of the analyses. The authors had complete control and authority over the design, data analysis, interpretation, manuscript preparation, and the decision to submit this manuscript to The American Journal of Medicine for publication. The manuscript was submitted to GSK before submission for publication. All authors meet criteria for authorship and have seen and approved the final version of this manuscript.

PII: S0002-9343(08)01176-5

doi: 10.1016/j.amjmed.2008.09.046

© 2009 Elsevier Inc. All rights reserved.